Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Oaktree Acquisition Corp. III Life Sciences Unit (OACCU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: OACCU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 2.52% | Avg. Invested days 83 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 9.99 - 10.99 | Updated Date 06/14/2025 |
52 Weeks Range 9.99 - 10.99 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Oaktree Acquisition Corp. III Life Sciences Unit
Company Overview
History and Background
Oaktree Acquisition Corp. III was a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The 'Life Sciences Unit' portion refers to the company's focus on identifying a target in the life sciences sector for such a combination. As it was a SPAC (Special Purpose Acquisition Company), its lifespan was dependent on completing a deal within a specified timeframe.
Core Business Areas
Leadership and Structure
As a SPAC, leadership typically consisted of a management team with experience in finance and the life sciences sector. The structure was relatively simple, designed to identify and acquire a target company.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
The life sciences industry is characterized by rapid innovation, high regulatory hurdles, and significant investment in research and development.
Positioning
As a SPAC, Oaktree Acquisition Corp. III's positioning was that of a potential investor and acquirer of a promising life sciences company. Its competitive advantage hinged on its access to capital and the experience of its management team.
Total Addressable Market (TAM)
The Total Addressable Market (TAM) for the life sciences is vast, encompassing pharmaceuticals, biotechnology, medical devices, and diagnostics. Oaktree Acquisition Corp. III would target a specific segment within this large TAM based on its investment thesis.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Access to capital
- Flexibility to pursue various deal structures
Weaknesses
- Dependence on finding a suitable target
- Time constraints for completing a deal
- Potential for shareholder dilution
Opportunities
- Growing demand for life sciences products and services
- Increasing investment in research and development
- Potential for consolidation in the industry
Threats
- Intense competition for acquisition targets
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
Competitive Landscape
As a SPAC, its competitors were other SPACs and traditional private equity firms seeking to acquire life sciences companies.
Growth Trajectory and Initiatives
Historical Growth:
Future Projections:
Recent Initiatives:
Summary
Oaktree Acquisition Corp. III was a SPAC focused on the life sciences sector, which had the potential to be a strong investment vehicle if it could identify and acquire a suitable target. Its strengths included an experienced management team and access to capital. However, it faced weaknesses such as time constraints and competition from other investors. Ultimately, success hinged on finding a compelling acquisition opportunity.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The information may not be complete or accurate. SPACs are inherently risky investments.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oaktree Acquisition Corp. III Life Sciences Unit
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2024-10-24 | CEO & Director Mr. Zaid Pardesi | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | |
Full time employees - | |||
Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.